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40 Poster Session-Ipredicators of OS: age, gender, diagnosis, KPS, stem cell source,
LVEF, resting HR and O2sat, reaching target HR, DLCOcorr
and FEV1. For allogeneic BMT, multivariate analysis demon-
strated age\40 years (RR 5 0.37, p 5 0.03) and higher FEV1
(RR 5 0.98, p 5 0.02) had a decreased risk and KPS#80 (RR
5 3.19, p 5 0.01) had increased risk of death. For autologous
BMT, multivariate analysis demonstrated significantly decreased
risk of death for higher baseline HR (RR 5 0.95, p 5 0.002),
baseline O2sat (RR 5 0.69, p 5 0.01), LVEF (RR 5 0.91, p
5 0.04) and DLCOcorr (RR 5 0.97, p 5 0.02). Early OS
may be predicted using simple measures of cardiac, pulmonary
and exercise functions pre-BMT.98
PRE-TRANSPLANT CLONAL CYTOGENETIC ABNORMALITIES IN STEM
CELLS USED FOR AUTOLOGOUS STEM CELL TRANSPLANT FOR RELAPSED
NON-HODGKIN LYMPHOMA IS A PREDICTOR OF RELAPSE
Rojas, A.M., De Vos, S., Pinter-Brown, L., Paquette, R., Schiller, S.,
Territo, M.C. UCLA, Los Angeles, CA
Autologous stem cell transplant is used for chemotherapy sensitive
relapsed Non-Hodgkin Lymphoma (NHL). Patients who receive an
autologous stem cell transplant after high dose chemotherapy for re-
lapsed NHL have significantly superior survival compared to those
receiving conventional chemotherapy. Relapsed patients who
achieve a second remission are treated with myeloablative chemo-
therapy followed by autologous stem cell transplant. These patients
can achieve 5-year event free survival close to 50% and 5-year overall
survival of greater than 50%. We performed a retrospective analysis
of our center’s transplant data and reviewed pre-transplant cytoge-
netic analysis on the patient’s collected stem cells. 259 patients un-
derwent autologous stem cell transplant from 1998 through 2007
for relapsed NHL. Cytogenetic evaluations of the patient’s pre-
transplant stem cells had been done to look for evidence of MDS
or characteristics of their lymphoma. Clonal cytogenetic abnormal-
ities were found in 12 of the 259 patients. Two of these patients died
within 45 days of transplant without evidence of relapse. One from
infection and a second from non-treatment related causes. Nine of
the remaining 11 (81%) patients with clonal cytogenetic abnormal-
ities have relapsed and died. All patients relapsed with their original
lymphoma. The cytogenetic abnormalities were varied. Out of the 9
relapses, 3 had cytogenetic abnormalities in the stem cells that are as-
sociated with lymphoma, 2 that are associated with AML, 1 that is
associated with MDS, and 2 were abnormalities whose significance
was unknown. In one patient cytogenetic changes of the original
lymphoma were identified. The patients that had clonal cytogenetic
abnormalities in their collected stem cells had an 81% relapse rate as
opposed to 30% in the patients whose stem cells had a normal kar-
yotype. Our findings show that cytogenetic changes in the collected
stem cells are associated with a higher rate of lymphoma relapse.99
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) WITH A PCR-NEG-
ATIVE GRAFT WAS ASSOCIATED WITH A FAVORABLE OUTCOME FOR
CORE-BINDING-FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML)
Nakasone, H.1,2, Izutsu, K.1, Wakita, S.3, Yamaguchi, H.3, Muramatsu-
Kida, M.1, Usuki, K.1 1Kanto Medical Center NTT EC, Shinagawa-ku,
Tokyo, Japan; 2SaitamaMedical Center, Jichi Medical University, Grad-
uate School; 3Nippon Medical School
Although core binding factor acute myeloid leukemia (CBF-
AML) is generally considered to be a low-risk form of AML, the sur-
vival rate is still 50–60%. To evaluate the effectiveness of autologous
stem cell transplantation (ASCT) with a PCR-negative graft, we an-
alyzed a series of consecutive CBF-AML patients. Between 1997 and
2006, 18 patients aged less than 60 years were referred under a diag-
nosis of CBF-AML. Peripheral blood stem cells (PBSC) were col-
lected after a second or further course of post-remission therapy.
When more than 2.0 106/kg CD34-positive cells with minimal re-
sidual disease (MRD) undetectable by nested PCR had been col-
lected, ASCT was performed with busulfan, etoposide and
cytarabine combined with granulocyte colony-stimulating factor.
Event-free survival (EFS) and complications of ASCT were then as-sessed. Fourteen of the 18 patients received ASCT. The median ob-
servation period was 4.4 years. The 5-year EFS was 93% for ASCT
patients, despite the presence of adverse factors. In 8 of 10 patients
who had detectable MRD in the bone marrow before ASCT,
MRD became undetectable after ASCT. Neutrophils recovered
promptly within 2 weeks, but platelets recovered relatively slowly.
Half of the patients suffered from varicella zoster virus infection. Al-
though one case of myelodysplastic syndrome occurred, there was no
case of relapse. ASCTwith a PCR-negative graft was associated with
excellent EFS. For patients with CBF-AML, especially with adverse
factors or remnant MRD in the bone marrow, this strategy is the
treatment of choice.100
FEBRILE REACTIONS OCCURRING WITH SECOND CYCLE OF HIGH DOSE
MELPHALAN AND STEM CELL TRANSPLANTATION IN PATIENTS WITH
AL AMYLOIDOSIS: A ‘‘MELPHALAN RECALL’’ REACTION
Rosenzweig, M.A.1, Seldin, D.C.1, Remick, D.3, Skinner, M.2,
Quillen, K.1, Oran, B.2, Finn, K.T.1, Sanchorawala, V.1 1Boston Univer-
sityMedical Center, Boston,MA; 2Boston University Medical Center, Bos-
ton, MA; 3Boston University Medical Center, Boston, MA
Systemic AL amyloidosis is a clonal plasma cell disease character-
ized by the wide spread deposition of amyloid fibrils into tissues and
organs. Treatment for this disease is directed towards reducing the
production of amyloidogenic monoclonal light chains by attacking
the underlying plasma cell dyscrasia. Aggressive treatment with
high dose intravenous melphalan followed by autologous stem cell
transplantation (HDM/SCT) is effective in inducing hematologic
and clinical remissions and in extending survival. Tandem cycles of
HDM/SCT have been shown to increase hematologic complete re-
sponse (HCR) rates in patients with AL amyloidosis. Between April
1994 and July 2008, 57 patients with AL amyloidosis at Boston Uni-
versity medical center were treated with a second cycle of HDM/
SCT after failing to achieve a HCR following a first transplantation.
Eleven of 57 patients (19%) treated with tandem transplantation de-
veloped a high fever 12–24 hours following melphalan administra-
tion. Other clinical features noted in some of the patients include
hypotension, acute renal failure, and skin rash. Among the 11
patients described, there were 7 men and 4 women. The average
age was 53.5 years (range 41–60). The average peak temperature of
the 11 patients was 39.1oC (range, 38.1–39.4oC). All patients
experienced resolution of fever within 24–48 hours. Six of the 11 pa-
tients developed a rash and 5 developed hypotension that was re-
sponsive to intravenous fluids or pressors when indicated. Two of
the patients developed acute renal failure that improved following
resolution of the fever. In all 11 patients, workup for an infectious
etiology of fever was negative. One of the 11 patients described,
had cytokine measurements before, during and after the febrile
reaction. The concentration of several pro-inflammatory as well as
anti-inflammatory cytokines increased significantly. IL-6, a classic
endogenous, pyrogenic cytokine, increased 10 fold with this reaction
demonstrating a clear physiologic response correlating with the clin-
ical findings. We conclude that an unusual febrile reaction mediated
by pyrogenic cytokines can occur in patients with AL amyloidosis ex-
posed to a second cycle of high dose melphalan. While this reaction
has not been observed in patients with multiple myeloma treated in
similar fashion, clinicians should be aware of this phenomenon we
have termed a ‘‘melphalan recall’’ reaction in patients with AL amy-
loidosis treated with tandem cycles of HDM/SCT.101
CLINICAL PATHWAYS AND STANDARD OPERATING PROCEDURES: ES-
SENTIAL TOOLS FOR OUTPATIENT STEM CELL TRANSPLANT PROGRAMS
TREATING PATIENTS WITH AL AMYLOIDOSIS
Finn, K.T., Fennessey, S., Yanarella, L., Antonelli, C., Shelton, A.,
Daniel, S., Skinner, M., Seldin, D., Quillen, K., Sanchorawala, V. Boston
University Medical Center, Boston, MA
Clinical pathways (CPs) and standard operating procedures
(SOPs) are necessary for treating AL patients with high-dose mel-
phalan and stem cell transplantation (HDM/SCT) in the outpatient
setting. AL is a plasma cell dyscrasia in which abnormal proteins
Poster Session-I 41misfold, form fibrils and deposit in vital organs causing malfunction
and death. HDM/SCT can produce hematologic remissions and
prolong survival. HDM/SCT was developed for the treatment of
AL at BostonUniversityMedical Center in 1994. In 1996, treatment
was moved to the outpatient setting. The program has been FACT-
accredited since 2000. To date, we have performed 496 SCTs. 95%
of patients are offered outpatient treatment. While patients with se-
vere cardiac involvement are not candidates forHDM/SCT, patients
with less severe cardiac disease can undergo HDM/SCT, with inpa-
tient cardiac monitoring. The CP begins with an extensive multidis-
ciplinary team evaluation involving members from hematology,
nephrology, cardiology, pulmonology, neurology, psychiatry, nurs-
ing, nutrition, clinical research and the amyloid program. The eval-
uation involves 3 days of visits which assess organ involvement,
performance status, support network including their ability to phys-
ically and emotionally adhere to an outpatient treatment program as
well as to post-transplant follow-up, and candidacy for a research
protocol. Weekly meetings are held to discuss evaluation results
and determine eligibility before a patient can be scheduled. Once
treatment begins, daily rounds, including toxicity evaluations, phys-
ical exams, medication review and reinforcement of the treatment
plan are conducted. Oral and written instructions are provided re-
garding expected toxicities, symptom management and emergency
contacts. Prophylactic treatment with antiemetic, antibacterial, anti-
viral, antifungal and growth factors are used. Themost common rea-
son for hospital admission is febrile neutropenia. Severe nausea,
vomiting, diarrhea, dehydration may also necessitate hospitalization.
CPs and SOPs were developed early on in the program and are
adhered to with a mechanism to document any deviations. CPs are
reviewed annually for revisions based on current peer-reviewed liter-
ature and program experience. Educational short courses are held
regularly for staff to insure adherence to CPs and SOPs. In summary,
outpatient HDM/SCT is a feasible treatment option for patients
with AL amyloidosis, provided treatment is conducted in an experi-
enced center.102
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION MAY
REVERSE RENAL FAILURE IN PATIENTS WITH MULTIPLE MYELOMA
Kazmi, S.M.A., Parikh, G.C., Lahoti, A., Mendoza, F., Hosing, C.,
Popat, U., Alousi, A.M., Weber, D.M., Wang, M., Champlin, R.E.,
Giralt, S.A., Qazilbash, M.H. UT - MDAnderson Cancer Center, Hous-
ton, TX
Background: Approximately 20% of patients with multiple my-
eloma (MM) have renal failure at diagnosis, and about 5% are di-
alysis-dependent. These patients may potentially benefit from
high-dose chemotherapy and autologous hematopoietic stem cell
transplantation (auto SCT). However, many of these patients are
considered ineligible for auto SCT due to concerns about in-
creased treatment-related toxicity. We evaluated the outcome of
46 patient with MM and renal failure, defined as serum creatinine
.2 mg/dl sustained for .1 month, who received auto SCT at our
institution.
Methods: Forty-six patients with a median age of 56 years (range:
29–72) received auto SCT between September 1997 and August
2006. Median serum creatinine and creatinine clearance (CrCl) at
auto SCT were 2.9 mg/dl (range 2.0 – 12.5) and 33 ml/min (range
8.7 – 63), respectively. Ten patients (22%) were dialysis-dependent.
Results: Median follow up in surviving patients was 34 months
(range 5–81). Complete (CR) and partial responses (PR) were seen
in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall
response rate of 75%. Two patients (4%) died within 100 days of
auto SCT. Grade 2–4 Non-hematological adverse events were
seen in 18 patients (39%) and included cardiac arrythmias, pulmo-
nary edema, hyperbilirubinemia. Median progression-free (PFS)
was 22.8 months and median overall survival OS has not yet been
reached. Kaplan-Meier estimates of 3-year PFS and OS were 36%
and 64%, respectively. Thirty patients (62.5%) are still alive after
a median follow up of 34 months, and 18 patients (39%) are alive
and progression-free. Significant improvement in renal function, de-
fined as an increase in GFR by 25% above baseline, was seen in 17
patients (37%). None of the 10 dialysis-dependent patients became
dialysis independent. A pre-transplant creatinine level of $3mg/dlwas associated with a significantly shorter overall survival (p 5
0.05, HR 2.8).
Conclusions: Auto SCT was safe and feasible in selected patients
with MM and renal failure, and was associated with a significant im-
provement in renal function in approximately one-third of the trans-
planted patients.103
CYTOREDUCTIVE REGIMEN CONTAINING RANIMUSTINE (MCNU), CAR-
BOPLATIN, ETOPOSIDE AND CYCLOPHOSPHAMIDE (MCEC) BEFORE AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(PBSCT) FOR RELAPSED OR REFRACTORY LYMPHOMA
Asakura, Y., Tanosaki, R., Kim, S.-W., Azuma, T., Kurosawa, S.,
Yakushijin, K., Maruyama, D., Mori, S.-i., Fukuda, T., Watanabe, T.,
Kobayashi, Y., Tobinai, K., Takaue, Y. National Cancer Center Hospital,
Chuo-ku, Tokyo, Japan
MCNU, a derivative of nitrosourea that was developed in Japan,
shows good penetration into CSF and might be expected to decrease
CNS relapse of lymphoid malignancies when used before transplan-
tation. However, its feasibility and efficacy have not been extensively
analyzed in adult patients with lymphoma. We retrospectively eval-
uated anMCEC regimen which consisted ofMCNU (200mg/m2 on
days -8 and -3), carboplatin (300 mg/m2 on days -7 through -4), eto-
poside (500 mg/m2 on days -6 through -4) and cyclophosphamide
(50 mg/kg on days -3 and -2) in 68 patients with lymphoma (median
age, 48 yr: range, 20–65 yr) who underwent autologous PBSCT at
our institution between Jan. 1999 and Feb. 2008. The diagnosis in-
cludedDLBCL (N5 33), FL (14), including 6 transformants, T-cell
lymphoma (12), and HL (9). The median time from diagnosis to
PBSCTwas 20 months (4–198 mo), and the median number of prior
chemotherapy regimens was 3 (2–7). 97% had ECOG PS\ 2, 41%
had prior XRT, 4% had bulky disease, 62% had stage III-IV disease,
28% had IPI at relapse of H/H-I. The disease status at PBSCT was
1st CR/PR in 15%, $ 2nd CR/PR in 72%, and NC/PD in 13%.
Grade (G) 4 non-hematological toxicities (CTCAE ver. 3.0) in-
cluded elevated transaminase (1), hyponatremia (1) and hypokalemia
(1). GI and CNS toxicities consisted of G3 mucositis (10), G3 diar-
rhea (27) and G2 seizure (1). There were no G4 cardiac, pulmonary
or renal toxicities except for one who died of treatment-related
MOF. The cumulative incidence of relapse at 2 yrs was 49 %. Of
33 relapses, 2 occurred newly in the CNS without any previous his-
tory.With a median follow-up of 24 months (3–80) after PBSCT for
surviving patients, the 2-yr OS and PFS were 68% (95% CI 55–
81%) and 50% (95% CI 38–63%), respectively. In univariate analy-
ses, T-cell phenotype (p\ 0.01), bulky disease (p\ 0.01), disease
status other than CR/PR (p\ 0.01), stage III-IV (P 5 0.03), IPI
(H/H-I, p \ 0.01) and treatment without rituximab (p \ 0.01)
were unfavorably associated with OS. Multivariate analysis con-
firmed that T-cell phenotype (HR 1.85; 95% CI 0.85–2.86, p \
0.01), bulky disease (HR 3.02; 95% CI 1.26–4.79, p\0.01), disease
status (HR 1.95; 95% CI 0.89–3.01, p\ 0.01), IPI (HR 2.66; 95%
CI 1.19–4.14, p \ 0.01) and treatment without rituximab (HR
4.12; 95% CI 1.14–7.10, p \ 0.01) were unfavorably associated
with OS. The results suggested that autologous PBSCT with the
MCEC regimen is a feasible and effective treatment option for re-
lapsed/refractory lymphoma.104
TIMING OF HIGH DOSE MELPHALAN (HDM) AND OUTCOMES FOR AU-
TOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH
MULTIPLE MYELOMA (MM)
Mahindra, A.1, Bolwell, B.1, Rybicki, L.2, Sobecks, R.1, Pohlman, B.1,
Andresen, S.1, Earl, M.1, Dean, R.1, Copelan, E.1, Kalaycio, M.1 1Cleve-
land Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
HDM is the most widely used preparative regimen for ASCT in
MM. The timing of HDM prior to transplantation has varied be-
tween studies. HDM is given on day –2 (2 days prior to stem cell
infusion) in some and on day –1 in others. At our institution,
HDM was initially given on day -2. Considering Melphalan un-
dergoes rapid hydrolysis in plasma with a short half-life in the or-
der of 60–90 minutes, administration on day -1 seemed feasible and
